Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its second quarter 2025 financial results announcement and corporate update for August 14, 2025, at 8:30 AM ET.
The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 94699) and webcast. A replay of the presentation will be made available in the Events section of Cellectar's Investor Relations website.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biofarmaceutica in fase avanzata specializzata nello sviluppo di farmaci per il trattamento del cancro, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 e un aggiornamento aziendale per il 14 agosto 2025, alle 8:30 AM ET.
L'azienda terrà una conference call accessibile tramite il numero verde 1-800-717-1738 (ID conferenza: 94699) e in webcast. Una registrazione della presentazione sarà disponibile nella sezione Eventi del sito web delle Relazioni con gli Investitori di Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), una empresa biofarmacéutica en etapa avanzada especializada en el desarrollo de medicamentos para el tratamiento del cáncer, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 y una actualización corporativa para el 14 de agosto de 2025, a las 8:30 AM ET.
La compañía realizará una llamada en conferencia accesible a través del número gratuito 1-800-717-1738 (ID de conferencia: 94699) y una transmisión en vivo. Una repetición de la presentación estará disponible en la sección de Eventos del sitio web de Relaciones con Inversionistas de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB)는 암 치료제 개발을 전문으로 하는 후기 임상 단계의 바이오제약 회사로, 2025년 8월 14일 오전 8시 30분(동부시간)에 2025년 2분기 재무 실적 발표 및 기업 업데이트를 예정하고 있습니다.
회사는 무료 전화번호 1-800-717-1738 (회의 ID: 94699)과 웹캐스트를 통해 컨퍼런스 콜을 진행할 예정입니다. 발표 녹음은 Cellectar 투자자 관계 웹사이트의 이벤트 섹션에서 다시 볼 수 있습니다.
Cellectar Biosciences (NASDAQ : CLRB), une société biopharmaceutique en phase clinique avancée spécialisée dans le développement de médicaments contre le cancer, a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 ainsi qu'une mise à jour d'entreprise pour le 14 août 2025 à 8h30 ET.
La société organisera une conférence téléphonique accessible via le numéro gratuit 1-800-717-1738 (ID de conférence : 94699) et une diffusion en webcast. Un replay de la présentation sera disponible dans la section Événements du site web Relations Investisseurs de Cellectar.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung von Krebsmedikamenten spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 sowie ein Unternehmensupdate für den 14. August 2025 um 8:30 Uhr ET geplant.
Das Unternehmen wird eine Telefonkonferenz abhalten, die über die gebührenfreie Nummer 1-800-717-1738 (Konferenz-ID: 94699) und per Webcast zugänglich ist. Eine Aufzeichnung der Präsentation wird im Bereich Veranstaltungen auf der Investor-Relations-Website von Cellectar verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time.
| Conference Call & Webcast Details: | |
| Date: | Thursday, August 14, 2025 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Conference ID: | 94699 |
| Webcast: | Click HERE |
A replay of the corporate presentation will be available on the Events section of the Company’s Investor Relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes: iopofosine I 131, a PDC designed to provide targeted delivery of iodine-131 (radioisotope), for which the FDA has granted Breakthrough Therapy Designation; CLR 121225, an actinium-225 based program being targeted to several solid tumors with significant unmet need, such as pancreatic cancer; and CLR 121125, an iodine-125 Auger-emitting program targeted in other solid tumors, such as triple negative breast, lung and colorectal, as well as proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
In addition, iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma (MM) and central nervous system (CNS) lymphoma, and the CLOVER-2 Phase 1b study, targeting pediatric patients with high-grade gliomas, for which Cellectar is eligible to receive a Pediatric Review Voucher from the FDA upon approval. The FDA has also granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug and two Fast Track Designations for various cancer indications.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: X, LinkedIn, and Facebook.
Investor Contact:
Anne Marie Fields
Precision AQ
212-362-1200
annemarie.fields@precisionaq.com
FAQ
When will Cellectar Biosciences (CLRB) report Q2 2025 earnings?
How can investors access Cellectar Biosciences' Q2 2025 earnings call?
What is Cellectar Biosciences' (CLRB) main business focus?
Where can I find a replay of Cellectar Biosciences' Q2 2025 earnings presentation?
